// App-Quantinova.ai

TCT-287 : Impact of Eligibility Criteria on Clinical Outcomes of Firehawk and XIENCE Coronary Drug-Eluting Stent in an All-Comers Randomized Trial

Researchers

Presenter

  • Yuichi Saito

Principal Investigators

  • Andreas Baumbach

  • Bo Xu

  • Henning Kelbæk

  • Niels van Royen

  • Ming Zheng

  • Paul Knaapen

  • Ton Slagboom

  • Tom Johnson

  • Georgios Vlachojannis

  • Lene Holmvang

  • Luc Janssens

  • Andrzej Ochala

  • Salvatore Brugaletta

  • Richard Anderson

  • Harald Rittger

  • Sergio Berti

  • Emanuele Barbato

  • Gabor Toth

  • Luc Maillard

  • Christian Valina

  • Pawel Buszman

  • Holger Thiele

  • Alexandra Lansky

Medical Centers

  • Shanghai Microport, Shanghai, China

  • OLVG, Amsterdam, Netherlands

  • Barts Heart Centre, London, United Kingdom

  • Roskilde Hospital, Roskilde, Denmark

  • Medical University of Silesia, Katowice, Poland

  • GCS ES Axium Rambot, Aix en Provence, France

  • University of Graz, Graz, Austria

  • Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

  • Lambe Institute for Translational Medicine and CURAM, National University of Ireland Galway, Galway, Ireland

  • Radboudumc, Nijmegen, Netherlands

  • Yale University School of Medicine, New Haven, Connecticut, USA

  • Universitäts-Herzzentrum Bad Krozingen, Bad Krozingen, Germany

  • Cardiovascular Research Center Aalst OLV Hospital, Aalst, Belgium

  • hospital clinic, barcelona, Spain

  • Maasstad Hospital, Rotterdam, Netherlands

  • Bristol Heart Institute, Bristol, United Kingdom

  • Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China

  • Universitatsklinikum Erlangen, Erlangen, Germany

  • Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland

  • University Hospital of Wales, Cardiff, United Kingdom

  • Fondazione Toscana Gabriele Monasterio, Massa, Massa and Carrara, Italy

  • Rigshospitalet, Copenhagen, Denmark

  • Heart Center Leipzig, University Hospital, Leipzig, Germany

  • Imlealdaziekenhuis, Bonheiden, Belgium

Locations

  • China

  • Denmark

  • Austria

  • Netherlands

  • Belgium

  • United Kingdom

  • Poland

  • United States

  • Spain

  • Germany

  • France

  • Ireland

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Myocardial infarction

  • Coronary Artery Disease

Biomarkers

  • N/A

Drug/Treatment

  • sirolimus

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved